Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Hansoh Pharma Re-Files for $500 Million to $1 Billion Hong Kong IPO

publication date: Apr 12, 2019

Hansoh Pharma, an established drug company headquartered in Lianyungang, Jiangsu province, has once again filed for a Hong Kong IPO, which is rumored to seek between $500 million and $1 billion in new capital. In September 2018, Hansoh filed to raise between $1 billion and $3 billion, but the company allowed the application to lapse after six months. Hansoh is a profitable drug company with $1.1 billion in revenue and more than $280 million in profits. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China